María José Terol

Also affiliated with Hospital Clínico Universitario de Valencia, Biomedical Research Institute, INCLIVA Health Research Institute

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial”.

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

Journal of Clinical Oncology(2022)10.1200/jco.21.02321

N/A

1.9DataRank · unranked

62 citations

Fátima De la Cruz, Ana Jiménez Ubieto, Javier López‐Jiménez, Alejandro Martı́n, María José Terol +18 more

IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia

Blood Advances(2023)10.1182/bloodadvances.2023010132

N/A

0DataRank · unranked

9 citations

Berta Pons-Brun, Núria Russiñol, Heribert Playà-Albinyana, Tycho Baumann, Martí Duran‐Ferrer +25 more